Menu

Search

  |   Business

Menu

  |   Business

Search

Faraday Pharmaceuticals Announces First-In-Human Trial of FDY-5301

SEATTLE - Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced the start of a Phase 1 clinical trial evaluating its lead compound FDY-5301.

The randomized, double blind, placebo-controlled trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single, escalating, intravenous doses of FDY-5301 versus placebo in healthy volunteers. FDY-5301 contains elemental iodine in its reduced form – iodide – formulated for intravenous administration.

Preclinical data have demonstrated the ability of FDY-5301 to diminish reperfusion injury in both cardiac and skeletal muscle in a range of different animal models and in multiple species. The Phase 1 trial is being conducted in Australia and is targeted to enroll approximately 40 subjects.

"It's gratifying to begin this first-in-human study following the promising preclinical findings to date, and less than six months after our initial 'GLP' toxicity studies were initiated. Our elemental reducing agents have demonstrated compelling activity in a number of animal studies, including models of cardiac reperfusion, radiation injury and organ transplantation," said Stephen A. Hill, M.D., Chief Executive Officer of Faraday. "We are working hard on our Phase 2 preparations in hope of providing new options to patients as expeditiously as possible."

Faraday Pharmaceuticals is a biopharmaceutical company focused on the research and development of elemental reducing agents (ERAs). These therapeutic agents have potential applications for treatment of critical care illnesses. The company is headquartered in Seattle. 

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

October 23 12:30 UTC Released

CAWholesale Trade MM

Actual

0.5 %

Forecast

0.5 %

Previous

1.5 %

October 23 12:30 UTC Released

USNational Activity Index

Actual

0.17 %

Forecast

Previous

-0.31 %

October 23 14:00 UTC 3131m

EZConsumer Confid. Flash

Actual

Forecast

-1.1 %

Previous

-1.2 %

October 24 00:30 UTC 661661m

JPNikkei Mfg PMI Flash

Actual

Forecast

Previous

52.9 bln $

October 24 06:45 UTC 10361036m

FRBusiness Climate

Actual

Forecast

110 %

Previous

110 %

October 24 07:00 UTC 10511051m

FRMarkit Serv Flash PMI

Actual

Forecast

56.9 %

Previous

57.0 %

October 24 07:00 UTC 10511051m

FRMarkit Comp Flash PMI

Actual

Forecast

57.0 Bln BRL

Previous

57.1 Bln BRL

October 24 07:00 UTC 10511051m

FRMarkit Mfg Flash PMI

Actual

Forecast

56.0 bln $

Previous

56.1 bln $

October 24 07:30 UTC 10811081m

ITMarkit Service Flash PMI

Actual

Forecast

55.6 Bln EUR

Previous

55.6 Bln EUR

October 24 07:30 UTC 10811081m

RUMarkit Comp Flash PMI

Actual

Forecast

57.7 %

Previous

57.7 %

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.